407 related articles for article (PubMed ID: 33615880)
1. Shift of conventional paradigm of heart failure treatment: from angiotensin receptor neprilysin inhibitor to sodium-glucose co-transporter 2 inhibitors?
Berezin AE; Berezin AA
Future Cardiol; 2021 May; 17(3):497-506. PubMed ID: 33615880
[TBL] [Abstract][Full Text] [Related]
2. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
Xiang B; Zhang R; Wu X; Zhou X
JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813
[TBL] [Abstract][Full Text] [Related]
3. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
[TBL] [Abstract][Full Text] [Related]
4. Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?
Abdelhamid M; Rosano G; Metra M; Adamopoulos S; Böhm M; Chioncel O; Filippatos G; Jankowska EA; Lopatin Y; Lund L; Milicic D; Moura B; Ben Gal T; Ristic A; Rakisheva A; Savarese G; Mullens W; Piepoli M; Bayes-Genis A; Thum T; Anker SD; Seferovic P; Coats AJS
Eur J Heart Fail; 2022 Sep; 24(9):1460-1466. PubMed ID: 35753058
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction.
Docherty KF; McMurray JJV
Int J Cardiol; 2019 Apr; 281():179-185. PubMed ID: 29891240
[TBL] [Abstract][Full Text] [Related]
6. The ability of modern therapy to improve the prognosis of patients with HF: role of angiotensin neprilysin inhibitors and sodium-glucose cotransporter inhibitors.
Mareev YV; Mareev VY
Kardiologiia; 2021 Jul; 61(6):4-10. PubMed ID: 34311683
[TBL] [Abstract][Full Text] [Related]
7. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
[TBL] [Abstract][Full Text] [Related]
8. Use of Sodium-Glucose Cotransporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors in Patients With Atrial Fibrillation and Heart Failure From 2021 to 2022: An Analysis of Real-World Data.
Alonso A; Morris AA; Naimi AI; Alam AB; Li L; Subramanya V; Chen LY; Lutsey PL
J Am Heart Assoc; 2024 Mar; 13(6):e032783. PubMed ID: 38456406
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic Therapy for Heart Failure with Preserved Ejection Fraction.
Peters AE; DeVore AD
Cardiol Clin; 2022 Nov; 40(4):473-489. PubMed ID: 36210132
[TBL] [Abstract][Full Text] [Related]
10. Combining sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors in heart failure patients with reduced ejection fraction and diabetes mellitus: A multi-institutional study.
Hsiao FC; Lin CP; Tung YC; Chang PC; McMurray JJV; Chu PH
Int J Cardiol; 2021 May; 330():91-97. PubMed ID: 33587940
[TBL] [Abstract][Full Text] [Related]
11. Obesity-Related Heart Failure With a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2.
Packer M; Kitzman DW
JACC Heart Fail; 2018 Aug; 6(8):633-639. PubMed ID: 29525327
[TBL] [Abstract][Full Text] [Related]
12. Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy.
Malgie J; Clephas PRD; Brunner-La Rocca HP; de Boer RA; Brugts JJ
Heart Fail Rev; 2023 Sep; 28(5):1221-1234. PubMed ID: 37311917
[TBL] [Abstract][Full Text] [Related]
13. A review of current key guidelines for managing high-risk patients with diabetes and heart failure and future prospects.
Lee MMY; Sattar N
Diabetes Obes Metab; 2023 Jul; 25 Suppl 3():33-47. PubMed ID: 37041663
[TBL] [Abstract][Full Text] [Related]
14. New paradigm shift in the pharmacotherapy for heart failure-where are we now and where are we heading?
Yoshikawa T
J Cardiol; 2023 Jan; 81(1):26-32. PubMed ID: 35227538
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of angiotensin receptor-neprilysin inhibitor and sodium-glucose cotransporter-2 inhibitors for patients with heart failure with reduced ejection fraction: a meta-analysis.
Huang Y; Fang C; Zhang Y; Ma L; Zhou H; Ye H
J Cardiovasc Med (Hagerstown); 2023 Feb; 24(2):123-131. PubMed ID: 36583980
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-Neprilysin Inhibition as a Paradigm for All?
Vaduganathan M; Desai AS
Curr Cardiol Rep; 2016 Nov; 18(11):115. PubMed ID: 27747488
[TBL] [Abstract][Full Text] [Related]
17. [A practical approach to guideline-directed pharmacological treatment for heart failure with reduced ejection fraction].
Soltani S; Böhm M; Frey N; Eden M; Abdin A; Bauersachs J
Dtsch Med Wochenschr; 2022 Jul; 147(14):931-938. PubMed ID: 35868319
[TBL] [Abstract][Full Text] [Related]
18. Health equity in heart failure.
Vijay A; Yancy CW
Prog Cardiovasc Dis; 2024; 82():55-60. PubMed ID: 38215916
[TBL] [Abstract][Full Text] [Related]
19. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
Albert NM; Tyson RJ; Hill CL; DeVore AD; Spertus JA; Duffy C; Butler J; Patterson JH; Hernandez AF; Williams FB; Thomas L; Fonarow GC
Am Heart J; 2021 May; 235():82-96. PubMed ID: 33497697
[TBL] [Abstract][Full Text] [Related]
20. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
